Breast cancer (BRCA) remains the most common malignant cancer in women worldwide. Although a range of treatments exists, options with fewer side effects are still limited. SIGLEC15 (sialic acid-binding immunoglobulin-type lectin 15), an emerging immunosuppressive transmembrane protein, is highly expressed across many solid tumors, including BRCA. Understanding its role could help design therapies that overcome the drawbacks of current standards.

An innovative biotech startup founded by researchers at Washington University School of Medicine in St. Louis has been acquired by Lunit, a leading company in developing AI-based technologies for cancer prevention and early detection. The WashU startup, Prognosia, was created to develop software that harnesses AI to analyze mammograms and more accurately predict a woman’s five-year risk of developing breast cancer.

Dana-Farber Cancer Institute researchers are leading four studies with important new findings in breast cancer, lung cancer, and bladder cancer at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. The studies will be presented both in-person and online from October 17 to October 21. 

Dana-Farber investigators will also present clinical trial results that report improved quality of life for metastatic breast cancer patients; new approaches, based on early investigations, to using blood tests to guide the treatment of kidney cancer; and new ways to analyze real-world data with artificial intelligence.